Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Eli Lilly and Company for the Transformative Bio-Hermes-002 Study
December 09, 2024 10:00 ET
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This...
Clinical Trial Supplies Industry Forecast Report 2025-2033: $4.79 Billion Market Soars as Chronic Disease Incidence Rises Globally
December 05, 2024 04:31 ET
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trial Supplies Market Global Forecast Report by Services, Phase, Therapeutic Area, End Use, Countries and Company Analysis 2025-2033" report...
Adaptive Research Welcomes Western Radiation Oncology to Expand Community Access to Pioneering Cancer Treatment Trials
December 04, 2024 08:00 ET
|
Adaptive Research Inc
Western Radiation Oncology has joined Adaptive Research’s growing network of community physician practices.
Clinical Trial Investigative Site Network Market Analysis Report 2025-2030, Featuring ICON, IQVIA, WCG Clinical, ClinChoice, SGS, FOMAT Medical Research, SMO-Pharmina, Xylem Research and More
December 03, 2024 05:15 ET
|
Research and Markets
Dublin, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trial Investigative Site Network Market Size, Share & Trends Analysis Report by Therapeutic Areas (Oncology, Cardiology), Phase (Phase I,...
Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insights Report 2024-2029: Innovent, MabWorks, and Biotheus are Making Substantial Progress
November 22, 2024 04:49 ET
|
Research and Markets
Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. ...
Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
November 21, 2024 08:00 ET
|
Science 37, Inc.
Science 37 contributes almost half (47%) of the U.S. enrollment for GSK Phase 3 rare disease study while bolstering participant retention figures.
Agenda Announced for 2025 MDA Clinical & Scientific Conference Featuring Leading Speakers Dedicated to Groundbreaking Research and Clinical Achievements in Neuromuscular Disease
November 14, 2024 09:00 ET
|
Muscular Dystrophy Association
New York, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association today announced the agenda including tracks and Chairs for the 2025 MDA Clinical & Scientific Conference being held...
Medeloop Secures $15.5 Million in Series A Funding to Accelerate Medical Research
November 13, 2024 08:00 ET
|
Medeloop
MENLO PARK, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medeloop, the pioneering medical research platform announces the close of its $15.5 million Series A funding round. Led by global venture...
Next Generation Sequencers (NGS) Market Set to Surge at 8.3% CAGR, to Reach USD 2.4 billion by 2031 | Transparency Market Research, Inc.
November 08, 2024 07:32 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Nov. 08, 2024 (GLOBE NEWSWIRE) -- The next generation sequencers (NGS) industry (차세대 시퀀서(NGS) 산업) was valued at US$ 1.2...
Collaborative effort to conduct a study aimed at improving the diagnosis of Alzheimer’s and related dementias for everyone
October 28, 2024 10:00 ET
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These...